In Vitro Diagnostics for Early Cancer Detection

Presented by

Charlie Chrisawn Exec Director, Program Strategy In Vitro Diagnostics, Michael Edwards Snr Director, Regulatory Affairs

About this talk

Topic : [In Vitro Diagnostics for Early Cancer Detection: The Evolution and Promise of Liquid Biopsy Technology] As liquid biopsies become more commonplace, gaining wider US Food and Drug Administration (FDA) acceptance and even becoming standard of care in some instances, the technology is giving rise to important new questions. In this webinar, the featured speakers will explore the technique’s growing importance in early cancer detection and address common questions about its use. The webinar will provide insights into developing an in vitro diagnostics test for early cancer detection with clinical, analytical and performance validation considerations. Attendees will learn how to approach single indication vs. multi-cancer screen indications, the advantages and disadvantages of lab-developed tests vs. premarket approval and the regulatory landscape for in vitro diagnostics. In addition, discover strategies for operationalizing large-scale clinical validation studies. Join this webinar on in vitro diagnostics for early cancer detection for a discussion on the evolution and promise of liquid biopsy technology. Please note: If we do not attend to your questions, we may follow up afterwards. Questions? Contact
Related topics:

More from this channel

Upcoming talks (0)
On-demand talks (96)
Subscribers (4594)
Premier Research is a clinical research company, dedicated to helping biotech, specialty pharma, and device innovators transform life-changing ideas and breakthrough science into new medical treatments. As a global company, Premier specializes in the use of innovative technologies for smart study design and trial management to deliver clean, conclusive data to sponsors. Whether it’s developing product lifecycle strategies, reducing clinical development cycle times, securing access to patients, navigating global regulations, maximizing the impact of limited rare disease data, or providing expertise in specific therapeutic areas, Premier is committed to helping its customers answer the unmet needs of patients across a broad range of medical conditions.